Summit Therapeutics, AstraZeneca, Daiichi Sankyo Collaborate on Ivonescimab Trial
Summit Therapeutics announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab, an investigational PD-1 / VEGF bispecific antibody, in combination with Datroway.
Story updates
06:30:29 AM UTC
SquawkNews
Daiichi Sankyo entered a clinical trial collaboration with AstraZeneca and Summit Therapeutics to evaluate Datroway with ivonescimab across tumors, starting with a phase 3 first-line TNBC study. Each party supplies its drug and shares costs; rights to each medicine are retained.Material DetailsCont…
06:30:36 AM UTC
SquawkNews
Summit Therapeutics announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab with Datroway across solid tumors, intending to start with a Phase III first-line TNBC study. Each company supplies its drug; AZ or Daiichi will sponsor.Material DetailsContext b…